Browse studies
Find your next paid study
26 recruiting studies matching your filters
Phase 1
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP): A Phase Ib/II Open-Label Trial
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival outcomes, even when treated with modern chemotherapy and radiation. Patients…
Pancreatic Ductal Adenocarcinoma (PDAC)Borderline Resectable Pancreatic CancerPancreatic Neoplasms
Estimated
~$10 – $6,250
University of VermontNCT07477418
Phase 1
A Phase I/Ib Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel or Gemcitabine, Nab-paclitaxel and Atezolizumab for Advanced Pancreatic Cancer
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with …
Pancreatic Ductal Adenocarcinoma (PDAC)
Estimated
~$10 – $8,750
ProDa BioTech, LLCNCT06182072